2022, Number 4
<< Back Next >>
Enf Infec Microbiol 2022; 42 (4)
Risk factors related to worst prognosis in patients with atypical pneumonia for SARS-COV-2: experience in a second level center
Gómez PJJ, Sierra HA, González VER, López ARR
Language: Spanish
References: 23
Page: 152-156
PDF size: 277.92 Kb.
ABSTRACT
Some comorbidities, including respiratory and non-respiratory infections, predispose to SARS-CoV-2 infection, and lead to
a worse prognosis during hospitalization for severe COVID-19.
Objective. To determine factors involved in a worse prognosis of hospitalized patients with COVID-19.
Methods. Data from the period from June 2020 to December 2021 were used; Risk factors such as diabetes, hypertension,
chronic obstructive pulmonary disease (COPD), asthma, immunosuppression, CKD, CLD, cancer, cardiovascular
disease, age, and medications used during hospitalization were included. Patients were classified into two groups: severe
and non-severe COVID-19 disease, both groups were compared using simple regression.
Results. The study included 1,529 patients, 392 cases of severe COVID-19 and 1,137 non-severe COVID-19 patients, 893
men (43-74 years) and 636 women (41-70 years). Mortality increased in people with diabetes, hypertension, and obesity;
patients who were using omeprazole, amines, or broad-spectrum antibiotics were associated with a worse prognosis,
while the use of steroids and heparin reduced the risk of progression to severe COVID-19.
Conclusions. The risk factors most related with a severe COVID-19 are diabetes, hypertension and obesity, these are
the ones with the worst prognosis and, therefore, increase hospital mortality, in addition to being the most common in
Mexicans. Recognizing them can reduce the incidence and mortality from severe COVID-19.
REFERENCES
The novel coronavirus pneumonia emergency responseepidemiology team. Vital surveillances: the epidemiologicalcharacteristics of an outbreak of 2019 novelcoronavirus diseases (covid-19). China, 2020”. China cdcWeekly, 2020; 2 (8): 113-122.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. ClinicalCharacteristics of 138 Hospitalized Patients With 2019Novel Coronavirus-Infected Pneumonia in Wuhan, China.JAMA. 2020;323(11):1061-1069.
Zhang JJ, Cao YY, Tan G, Dong X, Wang BC, Lin J, YanYQ, Liu GH, Akdis M, Akdis CA, Gao YD. Clinical, radiological,and laboratory characteristics and risk factors forseverity and mortality of 289 hospitalized COVID-19 patients.Allergy. 2021; 76(2):533-550. 4. Huang, C., Wang,
Y., Li, X. et al., “Clinical features of patients infected with2019 novel coronavirus in Wuhan, China”, Lancet, 2020;395: 497-506.
Liu, W., Tao, Z.-W., Wang, L. et al., “Analysis of factorsassociated with disease outcomes in hospitalized patientswith 2019 novel coronavirus disease”. Clin Med J(Inglaterra). 2020; 133: 1032-1038.
Zhang, W. et al., “Molecular and serological investigation of2019-nCoV infected patients: implication of multiple sheddingroutes”. Emerg Microbes Infect , 2020; 9: 386-389.
Li, R., Tian, J., Yang, F. et al., “Clinical characteristics of225 patients with covid-19 in a tertiary hospital near Wuhan,China”, J Clin Virol, 2020; 127: 104363.
Centers for Disease Control and Prevention (cdc),“People who are at higher risk for severe illness”,2020. Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/index.html.
Ran J, Song Y, Zhuang Z, Han L, Zhao S, Cao P, Geng Y,Xu L, Qin J, He D, Wu F, Yang L. Blood pressure controland adverse outcomes of COVID-19 infection in patientswith concomitant hypertension in Wuhan, China.Hypertens Res. 2020;43(11):1267-1276.
Cao, B., Wang, Y., Wen, D. et al., “A trial of lopinavir-ritonavirin adults hospitalized with severe covid-19”, N EnglJ Med 2020; 382 (19): 1787-1799.
Ou, M., Zhu, J., Ji, P. et al., “Risk factors of severe caseswith covid-19: a meta-analysis”. Epidemiol Infect 2020;148: e175.
Holman, N., Knighton, P., Kar, P. et al., “Risk factors for covid-19 related mortality in people with type 1 and type 2diabetes in England: a population-based cohort study”,Lancet Diabetes Endocrinol. 2020; 8 (10): 823-833.
Bode, B., Garrett, V., Messler, J. et al., “Glycemic characteristicsand clinical outcomes of covid-19 patients hospitalizedin the United States”, J Diabetes Sci Technol2020; 14 (4): 813-821.
Gao, F., Zheng, K.I., Wang, X.B. et al., “Obesity is a riskfactor for greater covid-19 severity”. Diabetes Care2020; 43 (7): e72-e74.
Cai, Q., Chen, F., Wang, T. et al., “Obesity and covid-19severity in a designated hospital in Shenzhen, China”.Diabetes Care 2020; 43 (7): 1392-1398.
Scala E, Abeni D, Tedeschi A, Manzotti G, Yang B, BorrelliP, et al. Atopic status protects from severe complicationsof COVID-19. Allergy. 2021;76(3):899-902.
Johnston, S.L., “Asthma and covid-19: is asthma a riskfactor for severe outcomes?”, Allergy. 2020; 75 (7):1543-1545.
Leung, J.M., Niikura, M., Yang, C.W.T. y Sin, D.D., “covid-
19 and copd”. Eur Respir J. 2020; 56 (2).19. Singh, S. y Khan, A., “Clinical characteristics and outcomesof coronavirus disease 2019 among patientswith preexisting liver disease in the United States: amulticenter research network study”. Gastroenterology.
2020; 159 (2): 768-771 e3.20. Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakhiya V,Hong S, Jhaveri KD, Fishbane S; Northwell COVID-19Research Consortium and the Northwell NephrologyCOVID-19 Research Consortium. Outcomes of patientswith end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020; 98(6):1530-1539.
Cheng, Y., Luo, R., Wang, K. et al., “Kidney disease isassociated with in-hospital death of patients with covid-19”. Kidney Int. 2020; 97: 829-838.
Brar G, Pinheiro LC, Shusterman M, Swed B, ReshetnyakE, Soroka O et al. COVID-19 Severity and Outcomesin Patients With Cancer: A Matched Cohort Study. J ClinOncol. 2020;38(33):3914-3924.
Xu, Z., Zhang, C. y Wang, F.S., “covid-19 in people withhiv”. Lancet hiv. 2020; 7 (8): e524-e526.
Full text